Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumorsBertrand Routy, Laurence Zitvogel, Emmanuelle Le Chatelier et al.|Science|2017Cited by 5.4k
Tumor mutational load predicts survival after immunotherapy across multiple cancer typesRobert Samstein, Ronald P. DeMatteo, Chung‐Han Lee et al.|Nature Genetics|2019Cited by 4.4k
OncoKB: A Precision Oncology Knowledge BaseDebyani Chakravarty, Nikolaus Schultz, Jianjiong Gao et al.|JCO Precision Oncology|2017Cited by 2.7k
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upDavid Planchard, Solange Peters, Sanjay Popat et al.|Annals of Oncology|2018Cited by 2.3k
Neoadjuvant PD-1 Blockade in Resectable Lung CancerPatrick M. Forde, Drew M. Pardoll, Jamie E. Chaft et al.|New England Journal of Medicine|2018Cited by 2.1k